

GE Healthcare

Amersham Cell Proliferation Labelling Reagent Bromo-deoxyuridine (BrdU), Fluoro- deoxyuridine (FdU)

Product Specification Sheet

Code: RPN201

Warning

For research use only.

Not recommended or intended for diagnosis of disease in humans or animals.

Do not use internally or externally in humans or animals.

Storage

Store refrigerated at 2–8°C.

Expiry

See outer packaging.

Safety warnings and precautions

All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.

Component

Supplied as an aqueous solution of 5-Bromo-2'-deoxyuridine and 5-Fluoro-2'-deoxyuridine.

Applications

The labelled reagent is supplied in the same formulation as used in the GE Healthcare cell proliferation kit (RPN20) and allows extended use of the kit where additional amounts of labelling reagent are required, for example, for *in vivo* studies.

For *in vitro* labelling, dilute labelling reagent 1:1000 with complete tissue culture medium, pre-warmed to 37°C. Incubate cells or tissue fragments in labelling medium at 37°C for required labelling time.

For *in vivo* use, inject animal with undiluted labelling reagent, using 1–2 ml/100 g body weight.

References

1. GRATZNER, H.G., *Science*, **218**, 474, (1982).
2. GONCHOROFF, N.J. *et al.*, *J.Immunol.Methods* **93**, 97-101, (1986).
3. CAMPANA, D. *et al.*, *J.Immunol.Methods* **107**, 79-88, (1988).

Legal

GE and GE Monogram are trademarks of General Electric Company. Amersham is a trademark of GE Healthcare companies

© 2006 General Electric Company – All rights reserved

GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specification and features shown herein, or discontinue the product described at any time without notice or obligation.

Contact your GE Healthcare representative for the most current information and a copy of the terms and conditions.

<http://www.gehealthcare.com/lifesciences>

GE Healthcare UK Limited
Amersham Place, Little Chalfont,
Buckinghamshire, HP7 9NA UK

GE Healthcare Bio-Sciences AB
Björkgatan 30 751 84,
Uppsala Sweden

GE Healthcare Europe GmbH
Munzinger Strasse 5 D-79111
Freiburg Germany

GE Healthcare Bio-Sciences Corp
800 Centennial Avenue PO Box 1327
Piscataway NJ 08855-1327 USA

GE Healthcare Bio-Sciences KK
Sanken Bldg 3-25-1, Hyakunincho Shinjuku-ku
Tokyo 169-0073 Japan



imagination at work